Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $4.7 million.

  • Iradimed's Cost of Revenue rose 1387.2% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 1321.91%. This contributed to the annual value of $16.9 million for FY2024, which is 966.12% up from last year.
  • Iradimed's Cost of Revenue amounted to $4.7 million in Q3 2025, which was up 1387.2% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Cost of Revenue registered a high of $4.7 million during Q3 2025, and its lowest value of $2.4 million during Q1 2021.
  • Over the past 5 years, Iradimed's median Cost of Revenue value was $3.8 million (recorded in 2023), while the average stood at $3.7 million.
  • Per our database at Business Quant, Iradimed's Cost of Revenue tumbled by 223.72% in 2021 and then surged by 3563.24% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Cost of Revenue stood at $3.1 million in 2021, then grew by 17.43% to $3.7 million in 2022, then rose by 10.21% to $4.0 million in 2023, then grew by 14.58% to $4.6 million in 2024, then increased by 1.72% to $4.7 million in 2025.
  • Its Cost of Revenue stands at $4.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.7 million for Q1 2025.